Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Construct an Organization While Chasing after a Web-based Degree - 2EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- 3Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 4Best Amusement Park in Europe: Where Do You Very much want to Visit?
- 5Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- Virtual reality opens doors for older people to build closer connections in real life
- Japan deploys the military to counter a surge in bear attacks
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- Share your number one city visit transport that leaves a mark on the world wake up!
- At least 11 killed in South Africa mass shooting
- Best Pizza Beating: What's Your #1?
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- Share your pick for the riding area that characterizes your surf undertakings!
